Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma

OBJECTIVE: Oral tyrosine kinase inhibitor has been shown to prolong progression-free survival (PFS) in epidermal growthfactor receptor (EGFR) mutation positive adenocarcinoma; however, the comparator arm has not included the current standard adenocarcinoma regimen (pemetrexed carboplatin induction f...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:ESMO Open
Autori principali: Patil, Vijay Maruti, Noronha, Vanita, Joshi, Amit, Choughule, Anuradha Bharat, Bhattacharjee, Atanu, Kumar, Rajiv, Goud, Supriya, More, Sucheta, Ramaswamy, Anant, Karpe, Ashay, Pande, Nikhil, Chandrasekharan, Arun, Goel, Alok, Talreja, Vikas, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar
Natura: Artigo
Lingua:Inglês
Pubblicazione: ESMO Open 2017
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5519810/
https://ncbi.nlm.nih.gov/pubmed/28761735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2017-000168
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi